Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

NCT00882102 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Decitabine
DRUG: Gemtuzumab ozogamicin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]